#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic thrombocytopenic purpura Hypoparathyroidism Thalassaemia alpha Loeys-Dietz syndrome Ischaemic stroke Liver transplant rejection Pulmonary sarcoidosis Haemophilia Angiosarcoma recurrent Fms-like tyrosine kinase 3 positive Herpes simplex Demyelination Kawasaki's disease Acute promyelocytic leukaemia Osteogenesis imperfecta More trials…

    Learn about Rare Diseases

    Paroxysmal nocturnal haemoglobinuria – Treatment Soft tissue sarcoma – Life with Disease Mastocytosis – Basic Information Leiomyosarcoma recurrent – Treatment Lymphatic malformation – Treatment KBG syndrome – Basic Information Waldenstrom’s macroglobulinaemia – Diagnostics Hereditary neuropathic amyloidosis Sarcoma – Life with Disease Krabbe’s disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Daptomycin Clemastine Fumarate Iph5201 Mifepristone Quetiapine Vindesine Sulfate Ads-013 Gemlapodect Gskvx000000008885 Vb10.16 Vanglusagene Ensiparvovec Ceftriaxone Trehalose Dihydrate (Ph.eur.) Fluorometholone Abbv-668 BUMETANIDE Methylprednisolone Acetate Satralizumab TRIACYLGLYCEROL LIPASE PIPOTIAZINE More therapies…

    Learn about Your Condition

    Diffuse large B-cell lymphoma Venous thrombosis Neuropathy peripheral Bile duct cancer Oesophageal adenocarcinoma Metastatic glioma Precocious puberty Acute promyelocytic leukaemia Microscopic polyangiitis Menopausal symptoms Antisynthetase syndrome Renal disorder Biliary tract disorder Multiple sclerosis relapse Craniopharyngioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Simeonidi Alex 2, Thessaloniki, 546 39, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Acalabrutinib
    • Doxorubicin
    • Pegfilgrastim
    Germany Greece

  • Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
    Belgium Czechia France Germany Greece Ireland +4

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Goserelin
    • Leuprorelin
    • Triptorelin
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Budesonide
    • Carboplatin
    • Cisplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Daratumumab
    • Bortezomib
    Czechia France Germany Greece Italy The Netherlands +3

  • A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Aciclovir
    • Linvoseltamab
    • Carfilzomib
    Austria Belgium Czechia France Germany Greece +4

  • Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pegfilgrastim
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Italy The Netherlands +4

  • Study on the Effect of Tinzaparin Sodium on Survival in Patients with Advanced Pancreatic Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Thrombosis
    • Tumour thrombosis
    Investigated Drugs:
    • Tinzaparin Sodium
    Greece

  • Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Gedatolisib
    • Alpelisib
    • Palbociclib
    Austria Belgium Bulgaria Czechia France Germany +6

  • Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Austria Czechia Germany Greece Hungary Latvia +3
Previous Page
1 2 3 4 5 6 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!